Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the
Board of Directors has tasked the company management to continue the
implementation of a separation of the company’s operations into two independent
companies, with the intention to obtain a separate listing on First North
Premium for the new commercial company based on Medivir’s current pharmaceutical
portfolio. The objective of the separation is to visualize the value of both the
commercial operations and the pharmaceutical projects that make up the R&D
The Board´s target timing is that a separation of Medivir’s operations into a
dedicated research and development company and a commercial pharmaceutical
company should be completed before Year-end. The existing operations would thus
be conducted by two clearly focused, specialized companies.
Further information about the new strategic path will be presented at a capital
markets day at a later date.
For further information, please contact:
Niklas Prager, CEO Medivir AB, phone +46 (0)8-407 64 30
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580
Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 8.30 CET on 31 August 2016.
Medivir is a research based pharmaceutical company with a research focus on
oncology and infectious diseases. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a portfolio of specialty care pharmaceuticals
on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.